AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Irish Independent)
LOSSES at Elan for this year could be as high as $200m following the announcement in the past two days that the company has sold two more products.
The sale of the North American marketing rights for migraine drug Frova for $55m and epilepsy treatment Zonegran for $130m would also see annual revenues plunge by$100m, analysts said.
Merrion Stockbrokers analyst Peter Frawley has estimated losses for this year of between $180m and $200m, up from $150m to $170m.
Elan should receive $280m in total for the two products when earn-outs are added in, which is less than the valuation put on them, Mr ...